Article
BRAF provides proliferation and survival signals in MSI colorectal carcinoma cells displaying BRAF(V600E) but not KRAS mutations.
The Journal of pathology - 1 Feb 2008
Preto A, Figueiredo J, Velho S, Ribeiro A S, Soares P, Oliveira C, Seruca R
Abstract excerpt
BRAF kinase is a downstream target of KRAS and activates the MAPK pathway. These two molecules are prone to mutations in sporadic microsatellite unstable (MSI) colorectal carcinomas (CRC) and BRAF V600E mutations are inversely associated with oncogenic KRAS mutations. The biological significance of BRAF V600E oncogenic activation is not well established in this type of tumour. We aimed to study proliferation and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
